通訊作者:

1. Lin CH, Tung YC, Chang TJ, Huang CN, Hwu CM*; for Taiwan Type 1 DM Consortium. Use of expert consensus to improve the diagnosis and management of type 1 diabetes mellitus. J Chin Med Assoc. 2022 1;85:741-746. [IF: 3.396]
2. Yen FS, Wei JC, Liu JS, Hsu CC, Hwu CM*. Clinical course of adolescents with type 2 diabetes mellitus: A nationwide cohort study in Taiwan. J Diabetes Investig. 2022 21. [IF: 3.690]
3. Wu TH, Lee IT, Ho LT, Sheu WH, Hwu CM*. Combined Lipid Goal Attainment in Patients with Type 2 Diabetes and Dyslipidemia: A Head-to-Head Comparative Trial of Statins. J Chin Med Assoc. 2022 20. [IF: 3.396]
4. Wu TH, Tsai SC, Lin HW, Chen CN, Hwu CM*. Increased serum levels of advanced glycation end products are negatively associated with relative muscle strength in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:118. [IF: 3.263]
5. Yen FS, Hwu CM*. Similarities and differences in the natural history of youth-onset type 2 diabetes between the West and Asia. J Diabetes Investig. 2022;13:941-943. [IF: 3.690]
6. Yen FS, Hsu CC, Wei JC, Hou MC, Hwu CM*. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Front Med (Lausanne). 2022 16;9:839456. [IF: 5.058]
7. Yen FS, Wei JC, Shih YH, Pan WL, Hsu CC, Hwu CM*. Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes. J Pers Med. 2022 28;12:702. [IF: 3.508]
8. Yen FS, Wei JC, Chiu LT, Hsu CC, Hwu CM*. Diabetes, hypertension, and cardiovascular disease development. J Transl Med. 2022 3;20:9. [IF: 8.459]
9. Yen FS, Wei JC, Shih YH, Hsu CC, Hwu CM*. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes. Sci Rep. 2022 28;12:3270. [IF: 4.996]
10. Yen FS, Hsu CC, Shih YH, Pan WL, Wei JC, Hwu CM*. Metformin and the Development of Asthma in Patients with Type 2 Diabetes. Int J Environ Res Public Health. 2022 5;19:8211. [IF: 4.614]
11. Wang JS, Wu YL, Ou HY, Yang YS, Hsu CC, Hwu CM . Trends in all-cause mortality and major causes of death between 2007 and 2018 among patients with diabetes in Taiwan. Frontiers in Endocrinology 2022 Aug 9;13:984137. [IF: 6.055]
12. Wu TH, Lin YC, Hwu CM. Ten-Year Atherosclerotic Cardiovascular Disease Risk Prediction for Postmenopausal Women: Impacts of Isolated Postchallenge Hyperglycemia. Medicine 2022 Sep 9;101(36):e30352 [IF: 1.817]
13. Yen FS, Hsu CC, Shih YH, Pan WL, Wei JC, Hwu CM. Metformin and the Development of Asthma in Patients with Type 2 Diabetes. International Journal of Environmental Research and Public Health 2022 Jul 5;19(13):8211. [IF: 4.614]
14. Fu-Shun Yen, James Cheng-Chung Wei, Lu-Ting Chiu, Chih-Cheng Hsu, Chii-Min Hwu. Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. Frontiers in Pharmacology 2022 [IF: 4.400]
15. Yen FS, Hsu CC, Hu KC, Hung YT, Hsu CY, Wei JC, Hwu CM*. Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes. Int J Environ Res Public Health. 2022 3;19:11045. [IF: 4.614]
16. Yen FS, Wei JC, Yip HT, Hsu CC, Hwu CM. Metformin use and the risks of herpes zoster and postherpetic neuralgia in patients with type 2 diabetes. Journal of Medical Virology 2022 (accepted) [IF: 20.693]
17. Yen FS, Hou MC, Pan CW, Liu JS, Hsu CC, Hwu CM*. The risk of severe hypoglycemia and mortality in patients with type 2 diabetes and discharged with acute liver injury.  Diabetes Care 2023 Jan 1;46(1):20-27. [IF: 17.155]
18. Yen FS, Wei JC, Shih YH, Hsu CY, Hsu CC, Hwu CM*. Metformin Use before Influenza Vaccination May Lower the Risks of Influenza and Related Complications. Vaccines (Basel). 2022 19;10:1752.               [IF: 4.961]
19. Fu-Shun Yen, James Cheng-Chung Wei, Yu-Tung Hung, Chih-Cheng Hsu, Hwu CM*. Long-term outcomes of the pay-for-performance program for patients with young-onset (20-40 years of age) type 2 diabetes. Diabetes Research and Clinical Practice. 2022,110136.      [IF: 8.180]
20. Yen FS, Wei JC, Yu TS, Hsu CY, Hsu CC, Hwu CM*. Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study. [IF: 4.614]
21. Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Frontier in Medicine. 2022 Dec [IF:5.058]
22. Yen FS, Hou MC, Wei JCC, Shih YH, Hsu CC, Hwu CM. Liver-related long-term outcomes of alpa-glucosidase inhibitors in patients with diabetes and liver cirrhosis. Front. Pharmacol 2022 Dec 13:1049094. [IF: 5.988]